Fortis Healthcare: Growth and Caution for Shareholders

Fortis Healthcare Ltd is a major player in India's healthcare sector, operating 36 facilities with around 4,000 beds across India, Nepal, Dubai, and Sri Lanka. With a market capitalization of ₹80,071 crore, the company has shown robust growth backed by strong private and institutional investor interest. Notably, Rekha Jhunjhunwala, often called "India’s Warren Buffett," holds a significant 4.1% stake. Domestic Institutional Investors collectively own 30%, including HDFC, Kotak, SBI Life, and Edelweiss, highlighting broad market trust. Financially, Fortis reported a compound annual sales growth of 11% over FY20–FY25, moving from ₹4,632 crore to ₹7,783 crore. Its EBITDA surged 21% CAGR, reaching ₹1,588 crore, and net profit jumped dramatically from ₹91 crore in FY20 to ₹809 crore in FY25. In the June 2025 quarter alone, sales hit ₹4,174 crore and profit stood at an impressive ₹455 crore, indicating continued momentum. Fortis’ share price soared 52% over five years, currently trading at ₹1,060 as of October 10, 2025. However, the stock commands a high PE of 87x, exceeding both its own 10-year median and the industry median, which could signal overvaluation. This premium might be justified if growth sustains, but risks exist if market euphoria cools. The company demonstrated resilience by navigating regulatory and legal challenges, including resolving issues from the Supreme Court’s investigation into its former promoters. With disputes settling and management focusing on disciplined capital allocation and geographic expansion, Fortis looks committed to long-term stability. For shareholders, Fortis offers exposure to a high-growth, recession-resistant sector, robust financials, and strong promoter credibility. The elevated PE, however, warrants caution; future gains hinge on sustained performance and prudent management. For those seeking growth in healthcare, Fortis remains a valuable watchlist candidate.